One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly

Background: Based on the CHIASMA OPTIMAL study, oral octreotide capsules (OOC) were recently approved in the US as a long-term maintenance therapy for patients with acromegaly previously responding to injectable octreotide or lanreotide, somatostatin receptor ligands (SRLs). Results on longer-term e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Samson, Susan Leanne, Nachtigall, Lisa B, Fleseriu, Maria, Molitch, Mark E, Giustina, Andrea, Ludlam, William Henry, Patou, Gary, Haviv, Asi, Biermasz, Nienke, Kennedy, Laurence, Sever, Mojca Jensterle, Manning, Patrick John, Elenkova, Atanaska, Melmed, Shlomo, Strasburger, Christian Joseph
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2021
Assuntos:
Neuroendocrinology and Pituitary
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090558/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1054
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados